Press Release FeedGet the RSS feed
Menu

Business Wire

Ephicacy Appoints Dr. Shekhar Thumake as Head of AI to Advance AI-Enabled Clinical Data Operations

Business Wire

Newly Created Leadership Role Accelerates the Responsible Application of AI Across Biometrics and Clinical Data Operations

ISELIN, N.J, August 18, 2026--Ephicacy today announced the appointment of Dr. Shekhar Thumake as head of AI, a new role that reflects the company's growing investment in artificial intelligence across its biometrics operations.

In this role, Thumake will lead Ephicacy's enterprise AI strategy and the development of agentic AI capabilities designed to connect and streamline clinical data workflows. He will collaborate closely with clients and delivery teams to identify high-value applications of AI while embedding interoperability, quality, governance, and regulatory considerations into standards-driven solution designs.

The appointment advances Ephicacy's strategy to embed AI across the clinical data life cycle while preserving the quality, transparency, governance, and regulatory rigor required in biometrics.

"Every advance in how we manage and analyze clinical data ultimately serves the patients waiting on new therapies," said CEO Tara Gladwell. "Shekhar brings a rare combination of clinical grounding and technical expertise, and he will help our teams apply AI where it creates the most value for the people we serve."

A physician, AI strategist, and technology leader with nearly two decades of experience, Dr. Thumake has built AI innovation functions and developed multiyear strategies focused on high-value opportunities across the clinical trial life cycle. His experience includes using CDISC's Unified Study Definitions Model (USDM) to support protocol digitization and interoperability, applying AI to unstructured clinical information to support patient eligibility assessment, protecting sensitive patient information through natural language technologies, and developing predictive capabilities to inform clinical trial site selection. He holds a medical degree, a master's degree in business management, and postgraduate credentials in data science and big data analytics.

"The most valuable applications of AI in biometrics will be those that combine scientific context, trusted data, interoperable standards, and human judgment," said Thumake. "Ephicacy has the biometrics expertise and client partnerships needed to turn that principle into practical solutions. I look forward to working with our teams and clients to build AI-enabled workflows that are efficient, transparent, and designed for the realities of regulated clinical research."

  1. Biotech & pharmaPfizer Inc.Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Companies: PfizerInvestigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S. NEW YORK, October 24, 2026--Pfizer I
  2. Biotech & pharmaIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--Landmark re
  3. AutomotivePerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerMore than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile WILMINGTON, Del., October 24, 2026 --
  4. ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of RecurrenceInterim analysis results from the Phase III DASL-HiCaP trial show a statistically significant 58% reduction in the risk of metastasis or death with NUBEQA® (darolutamide) versus placebo in addition to androgen deprivation therapy (ADT) and radiation therapy (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001) Four-year m
  5. FinanceSemtech CorporationSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand CAMARILLO, Calif., October 24, 2026--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices
  6. FinanceGenmab A/SGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerCompanies: IncytePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical tria